In the quiet moments of my academic and research journey, I was profoundly drawn to the mysteries of molecular biology and the urgent need for better diagnostic tools in oncology. Witnessing the challenges in early cancer detection, particularly in resource-limited settings, fueled my passion for translational research—where science meets real-world impact. My pursuit of innovation in cancer diagnostics deepened through my tenure as a Junior Research Fellow at ICGEB, New Delhi, and later as Ph.D. fellow in Molecular Medicine from Ulm University, Germany, where I explored IkappaB-Kinases as potential drug targets for castration-resistant prostate cancer.
I pursued research during later years as Principal Investigator under the Women Scientist-A (DST) program, where I investigated prostate cancer therapeutics. Furthering my commitment to advancing non-invasive diagnostics, I took on the role of Malaviya Postdoctoral Fellow at Banaras Hindu University, leading a research initiative to develop a urine-based detection tool for early prostate cancer diagnosis.
Recognizing the need to bridge the gap between research and clinical application, I founded MIRNOW LLP, a biotech startup dedicated to developing liquid biopsy-based diagnostics for cancer detection. As a Founder – CEO , I lead R&D, oversee biomarker discovery and clinical validation, drive strategic partnerships, and ensure regulatory compliance—pushing the boundaries of precision oncology in India.
Beyond my scientific endeavors, I co-founded Genetiks4U, a non-profit initiative aimed at public engagement in genetics and health awareness. My commitment to science communication, mentoring, and innovation has been recognized through multiple grants, awards, and patents in molecular diagnostics.
Now, as I stand at the intersection of research, entrepreneurship, and healthcare, I remain driven by a singular mission—to make cancer detection simpler, more accessible, and more effective. With an unwavering belief in the power of science to transform lives, I continue my journey to redefine cancer diagnostics and bring cutting-edge solutions to those who need them the most.
